EP0696271A1 - Derives de l'acide hydroxamique inhibiteurs de la cyclooxygenase et de la 5-lipoxygenase - Google Patents

Derives de l'acide hydroxamique inhibiteurs de la cyclooxygenase et de la 5-lipoxygenase

Info

Publication number
EP0696271A1
EP0696271A1 EP94913699A EP94913699A EP0696271A1 EP 0696271 A1 EP0696271 A1 EP 0696271A1 EP 94913699 A EP94913699 A EP 94913699A EP 94913699 A EP94913699 A EP 94913699A EP 0696271 A1 EP0696271 A1 EP 0696271A1
Authority
EP
European Patent Office
Prior art keywords
biphenylyl
formula
methyl
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP94913699A
Other languages
German (de)
English (en)
Inventor
Simon Teanby Hodgson
Peter John Wates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of EP0696271A1 publication Critical patent/EP0696271A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/64—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups singly-bound to oxygen atoms

Definitions

  • the present invention is concerned with hydroxamic acid derivatives having anti- inflammatory activity, with processes for their preparation, with pharmaceutical formulations containing said derivatives and with their use in medicine.
  • European Patent Specification 0196184 describes hydroxamic acid derivatives having anti-inflammatory activity by virtue of their ability to inhibit the enzymes 5- lipoxygenase and cyclooxygenase in the mammalian arachidonic acid cascade.
  • the compounds in question include those of formula
  • Y' is C2-10 alkenylene
  • R-l is Cj_4 alkyl, amino, C1-.4 alkylamino, or di-C ⁇ -4 alkylamino;
  • Ar is phenyl optionally substituted by one or more substituents independently selected from:
  • Cj_4 alkyl (which may itself be optionally substituted by one or more halogen atoms), C ⁇ _4 alkoxy, halo, nitro, amino, carboxy, C1-.4 alkoxycarbonyl, and hydroxy;
  • WO 90/12008, WO 92/10469, and WO 92/01682 also disclose compounds having lipoxygenase inhibitory activity.
  • R is Cj_4 alkyl optionally substituted by fluoro
  • D is C ⁇ _ ⁇ alkyl, phenyl or -N *R2 (wherein R* and R ⁇ are independently selected from hydrogen, C ] _4 alkyl, and phenyl); and
  • ring A and ring B are each optionally substituted by a group or groups independently selected from halo, cyano, nitro, hydroxy, C1-.4 alkyl, Cj_4 alkoxy, C1-.4 haloalkyl, C 1 .
  • compounds of formula (I) and their salts may exist in (R) or (S) enantiomeric forms.
  • the present invention therefore includes within its scope each of the individual (R) and (S) enantiomers of the compounds of formula (I) and their salts substantially free, ie associated with less than 5%, of the other enantiomer and mixtures of such enantiomers in any proportions including racemic mixtures containing substantially equal amounts of the two enantiomers.
  • the present invention does not extend to a compound of formula: (E)-N-[3-(4'-Cyano-3-biphenylyl)-l(S)-methyl-2-propenyl]acetohydroxamic acid, (E)-N-[3-(4'-Fluoro-3-biphenylyl)-l(S)-methyl-2-propenyl]acetohydroxamic acid,and (E)-N-[3-(4 , -Chloro-3-biphenylyl)-l(S)-methyl-2-propenyl]acetohydroxamic acid; or to mixtures thereof with the corresponding (R) enantiomer wherein the (R) enantiomer constitutes less than 50% of the mixture.
  • halo is meant fluoro, chloro, bromo, or iodo; preferably fluoro or chloro; most preferably, fluoro.
  • alkyl and alkoxy include straight and branched alkyl and alkoxy groups respectively.
  • haloalkyl and haloalkoxy refer to alkyl and alkoxy groups respectively, in which one or more hydrogens has been replaced by halo.
  • R is preferably Cj_4 alkyl in which one to three of the hydrogen atoms is optionally replaced by fluorine; more preferably Cj_4 alkyl; and is most preferably methyl.
  • D is suitably C]_4 alkyl, phenyl, or H 2 , preferably Cj_4 alkyl (eg. methyl) or -NH 2 , more preferably C1-4 alkyl, and most preferably methyl.
  • Ring A is suitably unsubstituted, or substituted by one to three groups independently selected from those listed in the definition of formula (I), for example, one or two substituents selected from halo, cyano, nitro, Cj_4 alkyl, C1-.4 alkoxy, Cj_4 haloalkyl, and C ⁇ _4 haloalkoxy.
  • Ring A has one substituent selected from halo, Cj_4 alkoxy (such as methoxy), and cyano in the 3- or 4-position relative to ring B or has two halo substituents in the 2- and 4-p ⁇ sitions relative to ring B.
  • Ring B is suitably unsubstituted, or substituted by one or two groups independently selected from those listed in the definition of formula (I), for example, one or two substituents selected from halo, cyano, nitro, C1-.4 alkyl, C1-.4 alkoxy, C1-.4 haloalkyl, and C ⁇ _4 haloalkoxy.
  • ring B is unsubstituted or substituted by one group selected from halo and cyano in the ortho position relative to ring A.
  • Group Y is preferably attached to ring B at the 3- or 4-position relative to ring A, and most preferably at the 3 -position.
  • R is Cj_4 alkyl optionally substituted by fluoro
  • D is Cj_4 alkyl, phenyl or -NR1R2 (wherein R! and R ⁇ are independently selected from hydrogen, C1-.4 alkyl, and phenyl);
  • ring A and ring B are each optionally substituted by a group or groups independently selected from halo, cyano, nitro, hydroxy, Cj_4 alkyl, C1-.4 alkoxy (said alkyl and alkoxy groups being optionally substituted by halo), -C(O)OR 3 -C(O)R 3 , -C(O) R 3 R 4 , -NR 3 R 4 , -NHCOR 3 , -NHCO R 3 , - HC(O) R 3 R 4 , - HSO 2 R 3 , - SO2NR R 4 (wherein R 3 and R 4 are independently selected from hydrogen, C ⁇ _4 alkyl and phenyl), and -S(O) n R 5 (wherein n is an integer of from 0 to 2 and R ⁇ is C1.4 alkyl, C6_IQ aryl (for example, phenyl or naphthyl), or Cg_ ⁇ 2 aralkyl); and salt
  • ring A and ring B are each optionally substituted by a group or groups independently selected from halo, nitro, hydroxy, C]_4 alkyl, Cj_4 alkoxy , C1-.4 haloalkyl, C ] _4 haloalkoxy, -C(O)OR 3 (wherein R 3 is as hereinbefore defined), and -NH 2 ;
  • EP 0196184 fall within the scope of EP 0196184 and represent a hitherto unrecognised sub-class having the advantageous properties previously referred to.
  • the present invention provides compounds of formula (I) wherein
  • D is C]_4 alkyl or phenyl
  • ring A and/or ring B are/is substituted as described above for formula (I) with the proviso that at least one substituent is a group selected from cyano, -C(O)NR R 4 , -NHCOR 3 , -NHCO 2 R 3 , -NHC(O)NR 3 R 4 , -NHSO 2 R 3 , -SO 2 NR 3 R 4 (wherein R 3 and R 4 are as hereinbefore defined), -S(O) n R ⁇ (wherein n and R ⁇ are as hereinbefore defined), C ⁇ _4 alkylamino, and di-Cj_4 alkylamino;
  • R is C1-.4 alkyl (such as methyl);
  • D is Cj-4 alkyl (such as methyl), phenyl, or -NH 2 ;
  • Ring A and ring B are optionally substituted by one or two substituents selected from halo, cyano, nitro, C1..4 alkyl, C1- alkoxy, C ⁇ . ⁇ haloalkyl, and C]_4 haloalkoxy; and
  • Y is attached to ring B at the 3- or 4- position relative to ring A
  • R is Cj_4 alkyl (such as methyl);
  • D is Cj_4 alkyl (such as methyl);
  • ring A and ring B are each optionally substituted by one or two groups independently selected from halo, C1-.4 alkoxy, and cyano, most suitably ring A has one substituent selected from halo, Cj_4 alkoxy, and cyano in the 3- or 4-position relative to ring B and ring B is unsubstituted or substituted by one group selected from halo and cyano in the ortho position relative to ring A; and
  • Y is attached to ring B at the 3- or 4- position relative to ring A;
  • Preferred compounds of formula (I) having excellent 5-lipoxygenase inhibitory activity include: (E)-N-[3-(4'-fluoro-3-biphenylyl)-l(R)-methyl-2-propenyl]-acetohydroxamic acid;
  • Salts of compounds of formula (I) which are suitable for use in medicine are those wherein the counterion is pharmaceutically acceptable.
  • salts having non- pharmaceutically acceptable counterions are within the ambit of the present invention, for use as intermediates in the preparation of compounds of formula (I) and their pharmaceutically acceptable salts and physiologically functional derivatives.
  • Salts according to the invention include ammonium salts, alkali metal salts such as those of sodium and potassium, alkaline earth metal salts such as those of calcium and magnesium, salts with organic bases such as dicyclohexylamine and N-methyl-D- glucamine, and salts with amino acids, such as arginine and lysine.
  • Examples of pharmaceutically acceptable acid addition salts include those derived from mineral acids, such as hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric, and sulphuric acids, and organic acids, such as tartaric, acetic, trifluoroacetic, citric, malic, lactic, fumaric, benzoic, glycollic, gluconic, succinic and methanesulphonic and arylsulphonic, for example p-toluenesulphonic, acids.
  • mineral acids such as hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric, and sulphuric acids
  • organic acids such as tartaric, acetic, trifluoroacetic, citric, malic, lactic, fumaric, benzoic, glycollic, gluconic, succinic and methanesulphonic and arylsulphonic, for example p-toluenesulphonic, acids.
  • physiologically functional derivatives chemical derivatives of compounds of formula (I) which have the same physiological function as the free compound of formula (I), for example, by being convertible in the body thereto.
  • examples of physiologically functional derivatives include compounds of formula (I) in which the hydroxyl of the hydroxamic acid functional group has been converted to a urethane, an alkyl ether, or an ester.
  • compounds of formula (I) and salts, solvates, and physiologically functional derivatives thereof have use in the prophylaxis and treatment of clinical conditions for which an inhibitor of the lipoxygenase or cyclooxygenase mediated arachidonic acid metabolic pathway is indicated, as demonstrated hereinafter in the 5-lipoxygenase and cyclooxygenase inhibition assays in which representative compounds of the present invention have been shown to be active.
  • spasmogenic conditions are those involving smooth muscle tissue, especially airway smooth muscle constriction such as asthma (including idiopathic bronchial asthma), bronchitis and arterial smooth muscle constriction such as coronary spasm (including that associated with myocardial infarction, which may or may not lead to left ventricular failure resulting in cardiac asthma), ischemia-induced myocardial injury, and cerebral spasm or 'stroke' (which may lead to central nervous pathophysiology).
  • Other examples include bowel disease caused by abnormal colonic muscular contraction such as the conditions known as 'irritable bowel syndrome', 'spastic colon' and 'mucous colitis'.
  • allergic conditions are extrinsic asthma, allergic skin diseases having a total or partial allergic origin, such as eczema, allergic bowel diseases (including coeliac disease), allergic eye conditions, such as hayfever (which may additionally or alternatively affect the upper respiratory tract), allergic rhinitis, and allergic conjunctivitis.
  • tumours are skin neoplasms, mastocytoma and other forms of cellular proliferation, both benign and malignant. It is to be noted that the effectiveness of the present compounds in the prophylaxis and treatment of tumours may arise from properties in addition to 5-lipoxygenase inhibition which also inhibit cell proliferation.
  • conditions involving blood platelet aggregation are those resulting from thrombosis, including 'strokes' having a total or partial thrombotic origin, coronary thrombosis, phlebitis and phlebothrombosis (the latter two conditions also possibly being associated with inflammation).
  • inflammatory conditions are those of the lungs, joints, eyes, bowel, skin, and heart; particularly those associated with the infiltration of leucocytes into inflamed tissue.
  • Inflammatory lung conditions include asthma, adult respiratory distress syndrome, bronchitis and cystic fibrosis (which may additionally or alternatively involve the bowel or other tissue(s)).
  • Inflammatory joint conditions include rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions.
  • Inflammatory eye conditions include uveitis (including ulceris) and conjunctivitis.
  • Inflammatory bowel conditions include Crohn's disease, ulcerative colitis and distal proctitis.
  • Inflammatory skin diseases include those associated with cell proliferation, such as psoriasis, eczema and dermatitis (whether or not of allergic origin). Inflammatory conditions of the heart include coronary infarct damage. Other inflammatory conditions include tissue necrosis in chronic inflammation, endotoxin shock, smooth muscle proliferation disorders (for example, restenosis following angioplasty), and tissue rejection following transplant surgery.
  • the present invention provides a method for the prophylaxis or treatment of a clinical condition in a mammal, such as a human, for which an inhibitor of the lipoxygenase or cyclooxygenase mediated arachidonic acid metabolic pathway, for example, a 5-lipoxygenase or cyclooxygenase inhibitor, is indicated; which comprises administration of a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.
  • the present invention further provides a method for the prophylaxis or treatment of a clinical condition in a mammal, such as a human, which clinical condition is a spasmogenic condition, an allergic condition, tumour formation, a condition involving blood platelet aggregation, or an inflammatory condition; which comprises administration of a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.
  • a compound of formula (I), or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof for use in medical therapy; particularly, for use in the prophylaxis or treatment of a clinical condition in a mammal, such as a human, for which an inhibitor of the lipoxygenase or cyclooxygenase mediated arachidonic acid metabolic pathway, for example, a 5-lipoxygenase or cyclooxygenase inhibitor, is indicated; for example a spasmogenic condition, an allergic condition, tumour formation, a condition involving blood platelet aggregation, or an inflammatory condition.
  • a suitable daily dose for a mammal suffering from, or likely to suffer from, any of the clinical conditions described hereinbefore is in the range O.l ⁇ g - 50mg of compound kilogram bodyweight.
  • the daily dose is typically in the range 0.05 - 50mg of compound/kilogram bodyweight, the most preferred dosage being from 0.05 to 20mg/kg bodyweight, for example, from 0.1 to lOmg/kg, administered as two or three sub-doses daily.
  • a suitable dose is in the range O.l ⁇ g - lOO ⁇ g of base per kilogram, typically about O.l ⁇ g/kg.
  • a suitable dose of the compound of the invention may be as specified in the preceding paragraph, but preferably is from 0.1 mg to lOmg of compound/kilogram bodyweight, the most preferred dosage being from 0.1 mg to 5mg/kg bodyweight.
  • the dose is typically in the range 2 ⁇ g - lOOmg/kg, preferably, from 5 ⁇ g to 5mg kg, for example from 0.01 to 1 mg/kg.
  • the present invention also provides the use of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof in the manufacture of a medicament for the prophylaxis or treatment of a clinical condition for which an inhibitor of the lipoxygenase or cyclooxygenase mediated arachidonic acid metabolic pathway, for example, a 5-lipoxygenase or cyclooxygenase inhibitor, is indicated; for example a spasmogenic condition, an allergic condition, tumour formation, a condition involving blood platelet aggregation, or an inflammatory condition.
  • a compound of formula (I) or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof in the manufacture of a medicament for the prophylaxis or treatment of a clinical condition for which an inhibitor of the lipoxygenase or cyclooxygenase mediated arachidonic acid metabolic pathway, for example, a 5-lipoxygenase or cyclooxygenase inhibitor, is indicated;
  • the present invention further provides a pharmaceutical formulation comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.
  • active ingredient means a compound of formula (I), or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.
  • the carrier or excipient must, of course, be compatible with the other ingredients in the formulation and must not be detrimental to the recipient.
  • the active ingredient may comprise from 0.1% to 99.9% by weight of the formulation. Typical unit doses of a formulation according to the invention contain from O.Olmg to lg of the active ingredient.
  • the active ingredient preferably constitutes from 1% to 2% by weight of the formulation, but the active ingredient may constitute as much as 10% w/w.
  • Formulations suitable for nasal or buccal administration typically contain from 0.1 to 20% w/w, for example, 2% w/w of the active ingredient.
  • Formulations according to the invention include those in a form suitable for oral, pulmonary, ophthalmic, rectal, parenteral (including subcutaneous, intramuscular and intravenous), intra-articular, topical, or nasal/buccal administration.
  • the formulations of the invention may conveniently be presented in unit dosage form and may be prepared by any method well known in the art of pharmacy. All such methods include the step of bringing the active ingredient into association with a carrier which constitutes one or more accessory ingredients.
  • the particle size of the active ingredient may be reduced before formulation, for example, by micronisation.
  • the formulations are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier, or both, and then, if desired, shaping the product into the required form.
  • Formulations according to the present invention which are suitable for oral administration may be in the form of discrete units such as capsules, cachets, tablets, or lozenges, each containing a predetermined amount of the active ingredient; in the form of a powder or granules; in the form of a solution, suspension, or a microfine suspension in an aqueous or non-aqueous liquid; or in the form of an oil-in-water or water-in-oil emulsion.
  • the active ingredient may also be in the form of a bolus, electuary, or paste.
  • a tablet may be made by compressing or moulding the active ingredient, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a disintegrant, compression aid, binder, lubricant, inert diluent, and/or surface active or dispersing agent.
  • Moulded tablets may be made by moulding, in a suitable machine, a mixture of the powdered active ingredient and a suitable carrier moistened with an inert liquid diluent.
  • Formulations for rectal administration may be in the form of a suppository inco ⁇ orating the active ingredient and a carrier such as cocoa butter, or in the form of an enema.
  • Formulations suitable for parenteral administration typically comprise a sterile aqueous or non-aqueous preparation such as an emulsion, suspension, or colloid of the active ingredient which is preferably isotonic with the blood of the recipient. Such formulations may also be freeze-dried and then reconstituted by addition of a sterile fluid shortly before administration.
  • a sterile aqueous or non-aqueous preparation such as an emulsion, suspension, or colloid of the active ingredient which is preferably isotonic with the blood of the recipient.
  • Such formulations may also be freeze-dried and then reconstituted by addition of a sterile fluid shortly before administration.
  • Formulations suitable for intra-articular administration may be in the form of a sterile aqueous preparation of the active ingredient, which latter may be in microcrystalline form, for example, an aqueous microcrystalline suspension.
  • Liposomal formulations and biodegradable polymer systems may also be used, for example to present the active ingredient for parenteral, intra-articular and ophthalmic administration.
  • Formulations suitable for topical administration include liquid and semi-liquid preparations such as liniments, lotions and applications; oil-in-water and water-in-oil emulsions such as creams, ointments and pastes; and solutions and suspensions such as drops.
  • the active ingredient may be presented as aqueous eye drops, for example, in the form of a 0.1 - 1.0% w/v solution.
  • Suitable formulations for administration by inhalation include fine particle dusts or mists which may be generated by means of various types of metered dose pressurised aerosols, nebulisers, or insufflators.
  • the particle size of the powder or droplets is typically in the range 0.5 - lO ⁇ m, preferably 1 - 5 ⁇ m, to ensure delivery into the bronchial tree.
  • a particle size in the range 10 - 500 ⁇ m is preferred to ensure retention in the nasal cavity.
  • Metered dose inhalers are pressurised aerosol dispensers, typically containing a suspension or solution formulation of the active ingredient in a liquefied propellant. During use, these devices discharge the formulation through a valve adapted to deliver a metered volume, typically from 10 to 150 ⁇ l, to produce a fine particle spray containing the active ingredient.
  • Suitable propellants include certain chlorofluorocarbon compounds, for example, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane and mixtures thereof.
  • the formulation may additionally contain one or more co-solvents, for example, ethanol, surfactants, such as oleic acid or sorbitan trioleate, anti-oxidants and suitable flavouring agents.
  • Nebulisers are commercially available devices that transform solutions or suspensions of the active ingredient into a therapeutic aerosol mist either by means of acceleration of a compressed gas through a narrow venturi orifice, typically air or oxygen, or by means of ultrasonic agitation.
  • Suitable formulations for use in nebulisers consist of the active ingredient in a liquid carrier and comprising up to 40% w/w of the formulation, preferably less than 20% w/w.
  • the carrier is typically water or a dilute aqueous alcoholic solution, preferably made isotonic with body fluids by the addition of, for example, sodium chloride.
  • Optional additives include preservatives if the formulation is not prepared sterile, for example, methyl hydroxy-benzoate, anti-oxidants, flavouring agents, volatile oils, buffering agents and surfactants.
  • Suitable formulations for administration by insufflation include finely comminuted powders which may be delivered by means of an insufflator or taken into the nasal cavity in the manner of a snuff.
  • the powder is contained in capsules or cartridges, typically made of gelatin or plastic, which are either pierced or opened in situ and the powder delivered by air drawn through the device upon inhalation or by means of a manually-operated pump.
  • the powder employed in the insufflator consists either solely of the active ingredient or of a powder blend comprising the active ingredient, a suitable powder diluent, such as lactose, and an optional surfactant.
  • the active ingredient typically comprises from 0.1 to 100 w/w of the formulation.
  • formulations according to the invention may include one or more additional ingredients such as diluents, buffers, flavouring agents, binders, compression aids, disintegrants, surface active agents, thickeners, lubricants, preservatives, for example, methyl hydroxybenzoate, anti-oxidants and emulsifying agents.
  • additional ingredients such as diluents, buffers, flavouring agents, binders, compression aids, disintegrants, surface active agents, thickeners, lubricants, preservatives, for example, methyl hydroxybenzoate, anti-oxidants and emulsifying agents.
  • the compounds of the invention may advantageously be employed in combination with one or more other therapeutic ingredients selected from an antibiotic (for example, an anti-bacterial), anti-fungal, or anti-viral agent, an anti- histamine (particularly a peripherally-acting anti-histamine), or a non-steroidal anti- inflammatory drug (NSAID).
  • an antibiotic for example, an anti-bacterial
  • a formulation according to the invention may contain, in addition to a compound of the invention, the further ingredient(s).
  • Y, R and the optional substituents on rings A and B are as defined for a compound of formula (I), with a suitable agent or agents to effect conversion of the N-hydrogen to an N-COD group, where D is (a) Cj_4 alkyl or phenyl, or (b) NR ⁇ R ⁇ where R* and R ⁇ are as hereinbefore defined;
  • Conversion (a) is typically carried out by treating a compound of formula (II) with an acylating agent, for example, an appropriate anhydride or activated acid, such as an acid halide, for example, acetyl chloride.
  • an acylating agent for example, an appropriate anhydride or activated acid, such as an acid halide, for example, acetyl chloride.
  • This reaction is suitably effected in an inert solvent, such as a halohydrocarbon, for example, dichloromethane, or an alkylbenzene, for example, toluene, at a temperature in the range -10°C to 150°C, for example 0-25° C in the presence of an organic base, such as a trialkylamine, for example, triethylamine.
  • Any N,O-diacylated product of this reaction may be mono-O- deacylated, suitably by treatment with an inorganic base, for example, potassium carbonate, or by treatment with
  • Conversion (b) is typically carried out by treating the compound of formula (II), or a salt thereof,
  • Rl and R ⁇ are to be hydrogen with a Group I cyanate, for example, potassium cyanate, in a non-polar solvent, such as tetrahydrofiiran (THF), in the presence of acid, such as a mineral acid, for example, dilute aqueous HC1, at a temperature in the range -10°C to 150°C, for example 0-25°C;
  • a Group I cyanate for example, potassium cyanate
  • THF tetrahydrofiiran
  • R 1 is to be Cj_4 alkyl or phenyl and R 2 is to be hydrogen, with the corresponding isocyanate R ⁇ NCO, in a suitable solvent, such as a halohydrocarbon, for example, dichloromethane, at a temperature in the range -10°C to 150°C, for example, 20-100°C;
  • a suitable solvent such as a halohydrocarbon, for example, dichloromethane
  • R and R 2 are each to be C 1.4 alkyl or phenyl, with the corresponding carbamoyl halide, for example RlR 2 NCOCl, in an inert solvent, such as a halohydrocarbon, for example, dichloromethane, in the presence of base, such as an organic base, for example, pyridine, at a temperature in the range -10°C to 150°C, for example, 20-100°C.
  • the compound of formula (II) may be obtained as the single enantiomer.
  • the compound of formula (II) may be obtained as a single enantiomer by : (i) separating the enantiomers obtained from the acylation reaction by any suitable method; (ii) effecting the mono-O- deacylation reaction by treatment with an enzyme capable of selectively reacting with one enantiomer, for example a lipase, to produce a mixture of the compound of formula (I) as a single enantiomer and the N,O-diacylated opposite enantiomer which can then be separated, for example by chromatography.
  • the separated N,O-diacylated product of this reaction may then be mono-O-deacylated by any of the methods described above also to yield the compound of formula (I) as
  • P' is a protecting group, such as an alkoxycarbonyl group, for example, -CO CH3, a cyclic ether, for example, tetrahydropyran, or t-butoxycarbonyl (Boc) and P" is a protecting group as described for P' or is hydrogen.
  • the conversion to a compound of formula (II) is suitably effected by acid or base hydrolysis as would be understood by the person skilled in the art.
  • the compound of formula (II), or a salt thereof may be prepared by treatment with an acid, such as an arylsulphonic acid, for example, para-toluenesulphonic acid; in a non-polar solvent, for example, toluene; at a moderate temperature, suitably in the range 10-100°, for example, 50-60°C.
  • the resulting salt of the compound of formula (II) may then optionally be hydrolysed to release the free base, for example, by chromatography on silica or by treatment with an inorganic base, such as a carbonate, for example, sodium carbonate.
  • rings A and B are optionally substituted as described for formula (I) and L is a suitable leaving group, for example, a halogen, (typically bromo or iodo) or a substituted sulphonate, for example, trifluoromethanesulfbnate; typically at elevated temperature, for example, 50-150°C, in a polar solvent, for example, N,N-dimethylformamide, in the presence of a catalyst, such as palladium (II) acetate with tri(o-tolyl)phosphine, and a suitable base, such as a trialkylamine, for example, triethylamine; or
  • this reaction may be effected by activation of the compound of formula (VI), for example by esterification of the hydroxyl group, typically using an acid anhydride (eg. acetic anhydride) or an acid halide (e.g. chloroacetyl chloride); in the presence of a base (eg. 4-dimethylaminopyridine, DMAP); and a catalyst, for example, tetrakis(triphenylphosphine) palladium (O); in a non-polar solvent, such as tetrahydrofuran (THF); at elevated temperature, for example, 40-120°C.
  • an acid anhydride eg. acetic anhydride
  • an acid halide e.g. chloroacetyl chloride
  • a base eg. 4-dimethylaminopyridine, DMAP
  • a catalyst for example, tetrakis(triphenylphosphine) palladium (O); in a non-polar solvent,
  • a chiral alcohol of formula (VI) is obtained, for example, (a) by using a chiral inducing catalyst, suitably an oxazaborohdine CBS catalyst (E.J. Corey et al Tet Letters 31(5), 611 (1990)) with the reducing agent, suitably catechol borane in an inert solvent, such as a cyclic ether (eg.THF) or an alkylbenzene (eg.
  • a chiral inducing catalyst suitably an oxazaborohdine CBS catalyst (E.J. Corey et al Tet Letters 31(5), 611 (1990)
  • the reducing agent suitably catechol borane in an inert solvent, such as a cyclic ether (eg.THF) or an alkylbenzene (eg.
  • toluene at low temperature, for example in the range -100°C to 50°C, or (b) by an enzymic reduction process.
  • the reduction may be carried out to give the racemic alcohol of formula (VI) using conventional reducing agents of organic chemistry for example, treatment with sodium borohydride in a polar solvent, such as an alcoholic solvent, at low temperature, for example in the range -50°C to 30°C.
  • the enantiomeric mixture of compounds of formula (VI) so obtained may be separated into the individual enantiomers by any suitable method, for example, by an enzymic resolution process, typically an enzyme catalysed acyl-transfer or hydrolysis reaction effected by treating the racemic compound of formula (VI) with an acyl donor, such as an enol ester (eg. vinyl acetate), an activated ester (eg. trifluoroethylbutyrate), or an acid anhydride (eg. succinic anhydride), in the presence of a suitable enzyme, such as a lipase, in an inert solvent, such as an aromatic solvent (eg.
  • an enzyme catalysed acyl-transfer or hydrolysis reaction effected by treating the racemic compound of formula (VI) with an acyl donor, such as an enol ester (eg. vinyl acetate), an activated ester (eg. trifluoroethylbutyrate), or an acid an
  • toluene at non-extreme temperature, for example in the range -20°C to 60°C, or followed by treatment with a suitable enzyme capable of selectively hydrolising one acylated enantiomer, such as a lipase.
  • a suitable enzyme capable of selectively hydrolising one acylated enantiomer, such as a lipase.
  • the resulting enantiomers may then optionally be separated because one of them is present in acylated form, by any appropriate method, for example by chromatography. If desired, the unwanted enantiomer may be "recycled" for example by racemic deacylation, suitably by hydrolysis; or
  • Y, P', and R are as hereinbefore defined.
  • This reaction may be carried out in the presence of a suitable catalyst system, for example, palladium (II) acetate/tri-(o-tolyl)phosphine, and a base, such as a trialkylamine, for example, triethylamine.
  • a suitable catalyst system for example, palladium (II) acetate/tri-(o-tolyl)phosphine
  • a base such as a trialkylamine, for example, triethylamine.
  • Subsequent removal of the hydroxyl protecting group P' may be effected by any suitable method, such as hydrolysis, for example, acid hydrolysis.
  • the compound of formula (VII) may be prepared by reaction of the corresponding aldehyde of formula (IX)
  • R is as defined for the compound of formula (I) and R 1 is C1 -.4 alkyl or, alternatively with acetone; in the presence of a base, such as sodium carbonate; in a polar solvent, such as THF, at a non-extreme temperature, for example -50° to 30°C.
  • a base such as sodium carbonate
  • a polar solvent such as THF
  • Compounds of formula (IX) may be prepared from compounds of formula (V) as defined above, typically by lithiation (for example with n-butyl lithium at low temperature, ie -100° to -20°C) followed by reaction with N,N-dimethylformamide (DMF).
  • lithiation for example with n-butyl lithium at low temperature, ie -100° to -20°C
  • DMF N,N-dimethylformamide
  • the compound of formula (VTI) may be prepared from a compound of formula (XI)
  • Compounds of formula (XI) may be prepared by reaction of a compound of formula (V) with acetylene; typically, by lithiation of the acetylene with, for example, butyl lithium.
  • L is as defined above for formula (V) and L' is either the same as L or is a different leaving group as understood by a skilled person.
  • This coupling may suitably be effected in the presence of a suitable catalyst, for example, tetrakis (triphenylphosphine) palladium (0) and an inorganic base, for example, sodium carbonate.
  • a suitable catalyst for example, tetrakis (triphenylphosphine) palladium (0) and an inorganic base, for example, sodium carbonate.
  • compounds of formula (V) may be prepared by coupling a compound of formula (XIII) as hereinbefore defined with the appropriate organometallic reagent (for example, the appropriately substituted PhMgX or PhZnX, where X is a halogen) which may be prepared in situ from the corresponding halide by treatment with the metal (e.g. Mg or Zn).
  • organometallic reagent for example, the appropriately substituted PhMgX or PhZnX, where X is a halogen
  • the coupling may be effected in an inert solvent, for example, THF, in the presence of a catalyst, for example, l,4-bis(diphenylphosphine)butane palladium (0) dichloride, palladium acetate, or tetrakistriphenyl phosphine palladium (0), at non- extreme temperature, for example 0-60°C.
  • a catalyst for example, l,4-bis(diphenylphosphine)butane palladium (0) dichloride, palladium acetate, or tetrakistriphenyl phosphine palladium (0), at non- extreme temperature, for example 0-60°C.
  • Enantiomeric compounds of the invention may be obtained (a) by separation of the components of the corresponding racemic mixture, for example, by means of a chiral chromatography column, enzymic resolution methods as described above, or preparing and separating suitable diastereoisomers, or (b) by direct synthesis from the appropriate chiral intermediates by the methods described above.
  • Optional conversion of a compound of formula (I) to a corresponding salt may conveniently be effected by reaction with the appropriate acid or base.
  • Optional conversion of a compound of formula (I) to a corresponding solvate or physiologically functional derivative may be effected by methods known to those skilled in the art.
  • the present invention provides novel intermediates for the preparation of compounds of formula (I), for example:
  • the stirred mixture was heated at 100°C, with exclusion of light, for 6 hours then cooled to room temperature. Further tri(o-tolyl)phosphine ( 369 mg ) and palladium (II) acetate ( 135 mg ) were added and heating resumed for an additional 5 hours, then the reaction mixture was cooled to room temperature.
  • the reaction mixture was poured into water ( 400 ml ) with stirring for 5 minutes, and then the mixture was extracted with diethyl ether ( 3 x 150 ml ). The extracts were combined, washed with water ( 3 x 200 ml ), dried over anhydrous magnesium sulphate, treated with charcoal and filtered. The filtrate was evaporated under reduced pressure to give an orange mobile oil ( 13.18 g ) from which the product ( 4,65 g ) and the mono-deprotected product ( 5.10 g ) were isolated by silica gel column chromatography, eluting with diethyl ether / petroleum ether bp 40-60°C ( 1 :2 ).
  • the salt was treated with excess saturated aqueous sodium hydrogen carbonate solution then the mixture was extracted with ethyl acetate ( 3 x 150 ml ). The combined extracts were washed with water ( 200 ml ), dried over anhydrous magnesium sulphate and filtered. The filtrate was evaporated under reduced pressure to give the product as a pale yellow, viscous oil ( 3.25 g ) which was used without further purification.
  • the reaction mixture was evaporated under reduced pressure and the residue partitioned between ether ( 400 ml ) and 2M hydrochloric acid ( 200 ml ), then the layers were separated.
  • the ether layer was washed with saturated aqueous sodium hydrogen carbonate solution ( 200 ml ) then with water ( 200 ml ) and dried over anhydrous magnesium sulphate. Filtration and evaporation of the filtrate under reduced pressure gave the product as a pale yellow / orange oil (4.22 g ) which was used without further purification.
  • the layers were separated and the ether layer was washed with 5% w/v aq. citric acid solution (100ml), then with water (100ml) and dried over anhydrous MgSO4. The mixture was filtered and the filtrate evaporated under reduced pressure to give a yellow oil (5.5g). The product was isolated as a colourless oil (4.0g) by passage through a short pad of silica gel, eluting with diethyl ether/40-60 o petroleum ether (1 :4).
  • the reaction mixture was poured into water ( 150 ml ) with stirring for 5 minutes, and then the mixture was extracted with ethyl acetate ( 3 x 75 ml ). The extracts were combined, washed with water ( 3 x 100 ml ), dried over anhydrous magnesium sulphate and filtered. The filtrate was evaporated under reduced pressure to give a tan, viscous oil ( 4.39 g ) which was used without further purification.
  • the reaction mixture was diluted with ethyl acetate ( 150 ml ) and then washed with water ( 75 ml ), 2M hydrochloric acid ( 75ml ) and finally with water ( 2 x 75 ml ).
  • the organic phase was dried over anhydrous magnesium sulphate, filtered and the filtrate evaporated under reduced pressure to give a tan / orange gum from which the product ( 1.02 g ) was isolated as a pale yellow gum by silica gel column chromatography, eluting with ethyl acetate.
  • 4'-Fluoro-3 -biphenylyl bromide (5.02g, 20mmol) was dissolved in dry THF (50ml) and the solution was stirred under dry nitrogen at -70°C.
  • a solution of n-butyllitbium (1.6M in hexanes)(12.5ml, 20mmol) was added dropwise, keeping the internal temperature below -55°C.
  • the solution was stirred at -70°C for 30 mins., then was added via a double-ended cannula, using nitrogen pressure, to a solution of tri-isopropyl borate (9.22ml, 40mmol) in dry THF (10ml) maintained at -70°C.
  • Example 11(b) (1.51g, 9.26mmol) (freshly purified by flash chromatography) was dissolved in THF (25ml), and the system was purged with nitrogen. Tetrakis(triphenylphosphine)palladium (0) (0.214g, 2 mol%) was added and the mixture was stirred under nitrogen until the catalyst had dissolved.
  • the product from Example 11(a) (4.0g, 9.26mmol) was added, followed by a solution of sodium carbonate (1.96g, 2eq.) in water (8ml).
  • Example 11(c) The product from Example 11(c) (1.39g, 5.47mmol) was stirred in methanol (30ml) at room temperature under nitrogen, and sodium borohydride (0.208g, 5.47mmol) was added portionwise over 15 mins. The mixture was stirred for 2 hours at room temperature, and was then evaporated in vacuo. The residue was partitioned between ethyl acetate and water, and the organic phase was separated and washed with semi-saturated brine, dried over anhydrous sodium sulphate, filtered and evaporated in vacuo to give the title product as a colourless amo ⁇ hous solid (1.32g).
  • Example 11(d) The product from Example 11(d) (1.32g, 5.15mmol) was dissolved in dry THF, and triphenylphosphine (2.025g, 7.73mmol, 1.5eq.) and N,O-bis(t- butoxycarbonyl)hydroxylamine (1.260g, 5.41mmol, 1.05eq.) were added. The mixture was stirred at -5°C under dry nitrogen and treated with a solution of diethyl azodicarboxylate (1.345g, 7.73mmol, 1.5eq.) in dry THF (5ml) added dropwise. The mixture was allowed to warm to room temperature and was stirred overnight.
  • Example 11(f) The product from Example 11(f) (l.Olg, 2.28mmol) was stirred in dry DCM (30ml) at 0°C under nitrogen, and dry pyridine (0.576g, 7.29mmol, 0.6ml, 3.2eq.) was added, followed by acetyl chloride (0.394g, 5.016mmol, 0.36ml, 2.2eq.). The mixture was allowed to warm to room temperature and was stirred overnight. The DCM was removed in vacuo, and the residue was partitioned between ethyl acetate and IN hydrochloric acid. The organic phase was separated, washed with IN hydrochloric acid, dried over anhydrous sodium sulphate, filtered and evaporated in vacuo. The crude product was purified by flash chromatography (ethyl acetate :hexane 1:2) to yield the title compound as a colourless oil (0.445g, 55% yield).
  • Example 11(g) The product from Example 11(g) (0.44g, 1.24mmol) was dissolved in methanol (20ml) and the solution was cooled in an ice/water bath. Anhydrous potassium carbonate (0.342g, 2.48mmol, 2eq.) was added, and the mixture was stirred for 90 mins. while being allowed to warm to room temperature. The solvent was removed in vacuo and the residue was partitioned between ethyl acetate and water. The organic phase was separated, washed with water, dried over anhydrous sodium sulphate, filtered and evaporated in vacuo. The crude product was purified by flash chromatography (ethyl acetate) to afford the title compound as a colourless resin (0.250g).
  • Example 26(c) The product from Example 26(c) (0.87g,2.345mmol) was dissolved in dry toluene (6ml) and p-toluenesulphonic acid (0.475g, 2.5mmol, 1.05eq.) was added. The mixture was heated, with stirring, at 50-60°C under nitrogen for 1.5 hours. The solvent was removed in vacuo, and the residue was purified by flash chromatography on silica, 4:96 methanol: dichloromethane eluent to afford the title compound (0.49 lg, 77%).
  • Example 26(d) The product from Example 26(d) (0.485g, 1.79mmol) was dissolved in DCM (25ml), and the solution was stirred in an ice-water bath under nitrogen. Pyridine (0.32ml, 3.93mmol, 2.2eq.) was added, followed by acetyl chloride (0.28ml, 3.93mmol, 2.2eq.). The reaction mixture was then allowed to warm to room temperature and stirred overnight. The solvent was removed in vacuo, and the residue was partitioned between ethyl acetate and IN hydrochloric acid. The organic phase was separated, washed with IN hydrochloric acid, dried over anhydrous sodium sulphate, filtered and evaporated in vacuo. The crude product was purified by flash chromatography (ethyl acetate: hexane 1 :2) to yield the title compound as a colourless oil (0.479g, 75% yield).
  • Example 26(e) The product from Example 26(e) (0.47g, 1.324mmol) was dissolved in methanol (20ml) and the solution was stirred under nitrogen at 0°C. Anhydrous potassium carbonate (0.365g, 2.648mmol, 2eq.) was added, and the mixture was stirred at 0°C for 2 hours. The solvent was removed in vacuo and the residue was partitioned between ethyl acetate and water. The organic phase was separated, washed with water, then with semi-saturated brine, dried over anhydrous sodium sulphate, filtered and evaporated in vacuo. The crude product was purified by flash chromatography (ethyl acetate) to afford the title compound as a colourless resin (0.280g).
  • the "active ingredient" in the following formulations is as defined above; preferably one of the compounds of Synthetic Examples 1 to 42.
  • Disperse the active ingredient in a small volume of the vehicle Gradually inco ⁇ orate this into the bulk to produce a smooth, homogeneous product. Fill into collapsible metal tubes.
  • Example C Cream for topical use
  • Example G Powder capsules for inhalation
  • Lactose (30-90 ⁇ m powder) 49.0 mg The powders were mixed until homogeneous and filled into suitably sized hard gelatin capsules (50mg per capsule).
  • the sorbitan trioleate and menthol were dissolved in the trichloro-fluoromethane.
  • the saccharin sodium and active ingredient were dispersed in the mixture which was then transferred to a suitable aerosol canister and the dichlorofluoromethane injected through the valve system.
  • This composition provides 0.5mg of active ingredient in each lOO ⁇ l dose.
  • Leukocytes were isolated from blood donated by normal aspirin-free volunteers by washing and centrifugation. A solution of the test compound in DMSO (lO ⁇ l, final concentration 0.01 - lOO ⁇ M) was added to the washed cell suspension (480 ⁇ l) and the mixture incubated at room temperature for 5 minutes. The tubes were placed on ice for 5 minutes and then stimulated with the calcium ionophore A-23187 (lO ⁇ l, final concentration 2.0 ⁇ M) for 5 minutes at 37°C. The reaction was terminated by boiling and the plasma concentration of LTB4 determined by Scintillation Proximity Assay (SPA).
  • SPA Scintillation Proximity Assay
  • Washed platelet suspensions from healthy human donors were prepared according to the method of Radomski et al (Thromb. Res., 30, 383-393, 1983). Tubes containing aliquots (0.5ml) of platelet suspension (10 ⁇ cells/ml) were incubated with test drug or vehicle for 5 minutes at room temperature before being placed on an ice bath for a further 5 minutes. The calcium ionophore A-23187 was added (final concentration 2 ⁇ M) and the tubes were incubated for 5 minutes at 37°C. The reaction was terminated by boiling for 2 minutes and the cellular precipitate removed for centrifugation. The thromboxane B 2 content of the supernatant was determined by radio-immunoassay.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur de nouveaux dérivés de l'acide hydroxamique de formule (I), et sur leur utilisation thérapeutique, particulièrement pour la prophylaxie ou le traitement d'états cliniques pour lesquels est indiqué un inhibiteur de la voie métabolique de l'acide arachidonique à médiation cyclooxygénasique et lipoxygénasique. L'invention porte également sur des formulations pharmaceutiques et des procédés de préparation de composés associés. Dans la formule (I), Y représente -C(Q)=C(Q')-((E)- ou (Z)-), Q et Q' étant choisis indépendamment parmi un hydrogène, un alkyle C1-4 et halo, ou Y représente -C C-; R représente alkyle C1-4 facultativement substitué par fluoro; D représente alkyle C1-4, phényle ou -NR?1R2 (où R1 et R2¿ sont choisis indépendamment parmi un hydrogène, alkyle C¿1-4?, et phényle); et le cycle A et le cycle B sont chacun substitués facultativement par un ou des groupes choisis indépendamment parmi halo, cyano, nitro, hydroxy, alkyle C1-4, alcoxy C1-4, haloalkyle C1-4, haloalcoxy C1-4, -C(O)OR?3, C(O)R3¿, -C(O)NR?3R4, -NR3R4¿, -NHCOR3, -NHCO¿2R?3, -NHC(O)NR3R4, -NHSO¿2?R?3, -SO¿2NR?3R4 (où R3 et R4¿ sont choisis indépendamment parmi un hydrogène, alkyle C¿1-4? et phényle), et -S(O)nR?5¿ (où n est un entier valant de 0 à 2 et R5 est alkyle C¿1-4?, aryle C6-10 (par exemple phényle ou naphtyle), ou aralkyle C8-12).
EP94913699A 1993-04-27 1994-04-26 Derives de l'acide hydroxamique inhibiteurs de la cyclooxygenase et de la 5-lipoxygenase Ceased EP0696271A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9308652 1993-04-27
GB939308652A GB9308652D0 (en) 1993-04-27 1993-04-27 Anti-inflammatory compounds
PCT/GB1994/000885 WO1994025430A1 (fr) 1993-04-27 1994-04-26 Derives de l'acide hydroxamique inhibiteurs de la cyclooxygenase et de la 5-lipoxygenase

Publications (1)

Publication Number Publication Date
EP0696271A1 true EP0696271A1 (fr) 1996-02-14

Family

ID=10734525

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94913699A Ceased EP0696271A1 (fr) 1993-04-27 1994-04-26 Derives de l'acide hydroxamique inhibiteurs de la cyclooxygenase et de la 5-lipoxygenase

Country Status (6)

Country Link
EP (1) EP0696271A1 (fr)
JP (1) JPH08509487A (fr)
AU (1) AU6574994A (fr)
GB (1) GB9308652D0 (fr)
WO (1) WO1994025430A1 (fr)
ZA (1) ZA942911B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3322885B2 (ja) * 1995-02-02 2002-09-09 日研化学株式会社 Ｎ−ヒドロキシウレア誘導体
ES2247604T3 (es) * 1995-06-12 2006-03-01 G.D. SEARLE & CO. Composiciones que comprenden un inhibidor de ciclooxigenasa-2 y un inhibidor de 5-lipoxigenasa.
WO2005061448A1 (fr) * 2003-12-24 2005-07-07 Monash University Compositions et methodes de traitement d'affections vasculaires
ES2569660T3 (es) 2007-06-08 2016-05-12 Mannkind Corporation Inhibidores de la IRE-1alfa

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU201300B (en) * 1985-03-16 1990-10-28 Wellcome Found Process for production of derivatives of aryl and medical compositions containing them as active substance
PL154186B1 (en) * 1987-07-15 1991-07-31 Wellcome Found Method for manufacturing arylic derivatives of the hydroxamic acid
EP0384594B1 (fr) * 1989-02-03 1993-10-27 The Wellcome Foundation Limited Dérivés d'aryl anti-inflammatoires
JPH06256285A (ja) * 1990-12-11 1994-09-13 Pfizer Pharmaceut Co Ltd ヒドロキサム酸誘導体およびその用途
US5169854A (en) * 1992-02-26 1992-12-08 Abbott Laboratories N-substituted-furylalkenyl hydroxamic acid and N-hydroxyurea compounds having lipoxygenase inhibitory activity

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
EP-A- 0 196 184 *
EP-A- 0 299 761 *
EP-A- 0 384 594 *
See also references of WO9425430A1 *
US-A- 5 169 854 *
WO-A-92/10469 *

Also Published As

Publication number Publication date
ZA942911B (en) 1995-10-26
JPH08509487A (ja) 1996-10-08
WO1994025430A1 (fr) 1994-11-10
AU6574994A (en) 1994-11-21
GB9308652D0 (en) 1993-06-09

Similar Documents

Publication Publication Date Title
EP1730103B1 (fr) Derives du formamide utile comme adrenocepteur
JP4036343B2 (ja) 疾患の治療のためのスルフォンアミド誘導体
EP0669311A1 (fr) Benzamides
JP2007529499A (ja) β２受容体アゴニストとしてのフェニルアミノエタノール誘導体
CH667264A5 (fr) Composes de phenethanolamine.
HU224823B1 (en) Substituted benzamidines,process for preparing the said compds. and pharmaceutical compns. contg. them
JPH10182583A (ja) 新規ヒドロキサム酸誘導体
US5686496A (en) Chemical compound, the preparation thereof and its use in pharmaceutical compositions
AU672810B2 (en) Hydroxamic acid derivatives and their use as anti-inflammatory compounds
US9499476B2 (en) Acetamide stereoisomer
EP1439164B1 (fr) Nouveaux composes de phenylethanolamine ayant une fonction d'excitation d'un beta2-accepteur et leur procede de preparation
JP2001518115A (ja) 新規なピリジン誘導体およびそれを含有する医薬組成物
EP0558563B1 (fr) Composes anti-inflammatoires
AP454A (en) Therapeutic compounds with hydroxamic acid derivatives.
EP0696271A1 (fr) Derives de l'acide hydroxamique inhibiteurs de la cyclooxygenase et de la 5-lipoxygenase
JP2002524553A (ja) 新規化合物
JP4033892B2 (ja) アドレナリン受容体として有用なホルムアミド誘導体
JPS6133147A (ja) フエネタノ−ルアミン化合物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950828

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

17Q First examination report despatched

Effective date: 19970129

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19970720